Conclusion Serum activin a may act as a clinicalmarker of liver cirrhosis in the future.
结论血清激活素a有可能成为新的肝硬化临床参考指标。
2
Results After 4 weeks and 8 weeks later, compared with the clinicalmarker, there are some alteration, and the treated group has more marked improvement.
结果两组患者的临床指标在治疗后4周、8周均较治疗前有明显改善，但治疗组较对照组改善更为显著。
3
C-reactive protein is widely used as a clinicalmarker to determine if a patient has an infection, but also if he or she may be at risk for disease later in life.